Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib in Relapsed/Refractory AML with FLT3 Mutations
NCT01657682Phase 2Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Oct 2012
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crenolanib in acute myeloid leukemia (AML), sponsored by AROG Pharmaceuticals, Inc.. Started Oct 2012; status: completed.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01657682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01657682.